Human Beta-Defensin 2 for Asthma and COPD Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for asthma and chronic obstructive pulmonary disease (COPD) are inadequate in preventing or curing the diseases, with steroid therapies only suppressing acute inflammatory symptoms and failing to address the underlying inflammatory processes effectively, and existing treatments are limited in their ability to target specific cytokines or administer medications through the airways for patients with compromised breathing.
Innovation Solution
The use of mammalian defensins, specifically human beta-defensin 2 (hBD-2) or truncated hBD-2, administered orally or intrapulmonary, to reduce airway hyperresponsiveness, inflammation, and cytokine production, rebalancing the immune system and normalizing cytokine levels, thereby addressing the inflammatory pathways and providing a treatment option for patients who cannot inhale drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroid therapy is used to suppress acute inflammatory symptoms, then symptom relief is achieved, but the underlying inflammatory processes are not effectively addressed and the disease is not prevented or cured
Solution Approach 1:
The patent extracts and targets specific pro-inflammatory cytokines (IL-4, IL-5, IL-13 for Th2; TNF-α, IFN-γ, IL-17 for Th1/Th17) rather than using broad-spectrum steroid suppression. This selective extraction of inflammatory pathways allows for more effective and targeted treatment of the underlying disease processes while avoiding the limitations of non-specific steroid therapy.
Solution Approach 2:
The invention changes the therapeutic parameter from non-specific anti-inflammatory suppression to specific cytokine pathway modulation. By using antibodies or agents targeting particular cytokines, the treatment parameters are refined to address specific inflammatory mechanisms, thereby improving both reliability of disease modification and effectiveness of treatment.
2Ease of manufacture
If single cytokine targeting is used (e.g., anti IL-4, anti IL-5, anti TNF-α), then specific inflammatory pathways are addressed, but treatment success is limited
Solution Approach 1:
The patent combines multiple cytokine targeting approaches into a single therapeutic regimen. By simultaneously addressing multiple pro-inflammatory cytokines across different pathways (Th2 and Th1/Th17), the treatment achieves synergistic effects that overcome the limitations of single-cytokine targeting and improves overall treatment success.
Solution Approach 2:
The invention creates a multi-functional therapeutic approach that can address diverse asthma phenotypes (both Th2 and Th1/Th17 driven) through a single treatment strategy. This universal approach targets multiple inflammatory pathways simultaneously, making the therapy effective across different disease subtypes rather than requiring separate treatments for each phenotype.
3Ease of operation
If current asthma treatments are used, then acute symptoms are suppressed, but there is no prevention or cure of the disease to date
Solution Approach 1:
The patent employs preliminary action by targeting and suppressing pro-inflammatory cytokines before they can fully drive pathological changes and disease progression. By intervening early in the inflammatory cascade through specific cytokine blockade, the treatment prevents disease development and progression rather than merely responding to established pathology.
Data Source
Figure 1
Figure 2
Figure 3a~4
AI summary
The present invention relates to methods for treatment or prevention of asthma, mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid refractory asthma, status asthmaticus, pneumonia, bronchiectasis, COPD, sarcoidosis, and lung cancer based on reducing airway hyper responsiveness, increasing pulmonary compliance, reducing lung inflammation, reducing inflammatory cell count in bronchoalveolar fluid and reducing cytokine production by administration of a mammalian α- and/or β-defensin.